Cargando…
Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors
SIMPLE SUMMARY: Patients with hematological malignancies have an increased risk of arterial thrombosis (ATE). Data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Out of 626 AML patients, 18 (2.9%) patients developed ATE in the median t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252977/ https://www.ncbi.nlm.nih.gov/pubmed/37297022 http://dx.doi.org/10.3390/cancers15113060 |
_version_ | 1785056298526572544 |
---|---|
author | Mitrovic, Mirjana Pantic, Nikola Sabljic, Nikica Bukumiric, Zoran Virijevic, Marijana Pravdic, Zlatko Cvetkovic, Mirjana Rajic, Jovan Bodrozic, Jelena Milosevic, Violeta Todorovic-Balint, Milena Vidovic, Ana Suvajdzic-Vukovic, Nada Antic, Darko |
author_facet | Mitrovic, Mirjana Pantic, Nikola Sabljic, Nikica Bukumiric, Zoran Virijevic, Marijana Pravdic, Zlatko Cvetkovic, Mirjana Rajic, Jovan Bodrozic, Jelena Milosevic, Violeta Todorovic-Balint, Milena Vidovic, Ana Suvajdzic-Vukovic, Nada Antic, Darko |
author_sort | Mitrovic, Mirjana |
collection | PubMed |
description | SIMPLE SUMMARY: Patients with hematological malignancies have an increased risk of arterial thrombosis (ATE). Data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Out of 626 AML patients, 18 (2.9%) patients developed ATE in the median time of 3 months. Our study showed that the risk of ATE was increased in AML patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. ABSTRACT: Background: Patients with hematological malignancies have an increased risk of arterial thrombotic events (ATEs) after diagnosis, compared to matched controls without cancer. However, data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Aim: The objectives of this study were to determine the incidence of ATE in non-promyelocytic-AML patients and to define the potential risk factors for ATE development. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. The primary outcome was the occurrence of confirmed ATE, defined as myocardial infarction, stroke or critical limb ischemia. Results: Out of 626 eligible AML patients, 18 (2.9%) patients developed ATE in the median time of 3 (range: 0.23–6) months. Half of these patients died due to ATE complications. Five parameters were predictors of ATE: BMI > 30 (p = 0.000, odds ratio [OR] 20.488, 95% CI: 6.581–63.780), prior history of TE (p = 0.041, OR 4.233, 95% CI: 1.329–13.486), presence of comorbidities (p = 0.027, OR 5.318, 95% CI: 1.212–23.342), presence of cardiovascular comorbidities (p < 0.0001, OR 8.0168, 95% CI: 2.948–21.800) and cytogenetic risk score (p = 0.002, OR 2.113, 95% CI: 1.092–5.007). Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. |
format | Online Article Text |
id | pubmed-10252977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102529772023-06-10 Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors Mitrovic, Mirjana Pantic, Nikola Sabljic, Nikica Bukumiric, Zoran Virijevic, Marijana Pravdic, Zlatko Cvetkovic, Mirjana Rajic, Jovan Bodrozic, Jelena Milosevic, Violeta Todorovic-Balint, Milena Vidovic, Ana Suvajdzic-Vukovic, Nada Antic, Darko Cancers (Basel) Article SIMPLE SUMMARY: Patients with hematological malignancies have an increased risk of arterial thrombosis (ATE). Data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Out of 626 AML patients, 18 (2.9%) patients developed ATE in the median time of 3 months. Our study showed that the risk of ATE was increased in AML patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. ABSTRACT: Background: Patients with hematological malignancies have an increased risk of arterial thrombotic events (ATEs) after diagnosis, compared to matched controls without cancer. However, data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Aim: The objectives of this study were to determine the incidence of ATE in non-promyelocytic-AML patients and to define the potential risk factors for ATE development. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. The primary outcome was the occurrence of confirmed ATE, defined as myocardial infarction, stroke or critical limb ischemia. Results: Out of 626 eligible AML patients, 18 (2.9%) patients developed ATE in the median time of 3 (range: 0.23–6) months. Half of these patients died due to ATE complications. Five parameters were predictors of ATE: BMI > 30 (p = 0.000, odds ratio [OR] 20.488, 95% CI: 6.581–63.780), prior history of TE (p = 0.041, OR 4.233, 95% CI: 1.329–13.486), presence of comorbidities (p = 0.027, OR 5.318, 95% CI: 1.212–23.342), presence of cardiovascular comorbidities (p < 0.0001, OR 8.0168, 95% CI: 2.948–21.800) and cytogenetic risk score (p = 0.002, OR 2.113, 95% CI: 1.092–5.007). Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30. MDPI 2023-06-05 /pmc/articles/PMC10252977/ /pubmed/37297022 http://dx.doi.org/10.3390/cancers15113060 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mitrovic, Mirjana Pantic, Nikola Sabljic, Nikica Bukumiric, Zoran Virijevic, Marijana Pravdic, Zlatko Cvetkovic, Mirjana Rajic, Jovan Bodrozic, Jelena Milosevic, Violeta Todorovic-Balint, Milena Vidovic, Ana Suvajdzic-Vukovic, Nada Antic, Darko Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title | Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title_full | Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title_fullStr | Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title_full_unstemmed | Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title_short | Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors |
title_sort | arterial thrombosis in patients with acute myeloid leukemia: incidence and risk factors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252977/ https://www.ncbi.nlm.nih.gov/pubmed/37297022 http://dx.doi.org/10.3390/cancers15113060 |
work_keys_str_mv | AT mitrovicmirjana arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT panticnikola arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT sabljicnikica arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT bukumiriczoran arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT virijevicmarijana arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT pravdiczlatko arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT cvetkovicmirjana arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT rajicjovan arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT bodrozicjelena arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT milosevicvioleta arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT todorovicbalintmilena arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT vidovicana arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT suvajdzicvukovicnada arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors AT anticdarko arterialthrombosisinpatientswithacutemyeloidleukemiaincidenceandriskfactors |